Predictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Call Transcript

Page 3 of 3

Josh Blacher: Thank you, Raymond. We concluded the fourth quarter of 2023 with 8.7 million in cash and cash equivalents compared to 22.1 million as of December 31, 2022, and 8.3 million in stockholders equity compared to 21.8 million as of December 31, 2022. Our net loss per share in 2023 declined approximately 50% to $3.48 for basic and diluted share, $6.98 per basic and diluted share for 2022. The company recorded revenue of 1.8 million in 2023, compared to 1.5 million in 2022. Revenues for the years ended December 31, 2023 and December 31, 2022 were primarily derived from our Eagan operating segment. The Eagan operating segment contributed 1.135 million and 1.064 million for the years ended December 31, 2023 and December 31, 2022 respectively, while the Pittsburgh operating segment contributed 493,000 and 359,000 respectively.

Operation expenses primarily consist of expenses related to product development, prototyping, and testing. Operation expenses decreased by 142,000 to 3.7 million in 2023, compared to 3.8 million in 2022. The decrease in operations expenses in 2023 is primarily due to approximately 132,000 lower research and development expenses related to office closures and approximately 52,000 lower related to staff expenses. These decreases were offset by higher cloud computing expenses associated with our Pittsburgh operating segments. Net cash used in operating activities was 13.2 million in 2023 compared to net cash use of 12.4 million in 2022. Cash used in operating activities increased in 2023, primarily due to cash operating losses as well as changes in working capital, including decreases in accrued expenses in contract liabilities, offset by an increase in accounts payable.

Net cash used in investing activities was 302,000 in 2023 compared to 476,000 in 2022. Cash used in investing activities decreased in 2023 primarily due to a decrease in the acquisition of property and equipment. Net cash provided by financing activities was 149,000 in 2023 compared to 67,000 in 2022. Cash provided by financing activities in 2023 was primarily related to proceeds refinancing insurance premiums over the insured period with a short-term note payable, while cash provided in 2022 was primarily proceeds from the issuance of common stock and warrants. The company incurred net losses of 14.0 million and 25.7 million for the years ended December 31, 2023 and December 31, 2022. That concludes the financial overview. We will now open the call for questions.

Operator.

Operator:

Raymond F. Vennare: Thank you all very much again for participating in this call. I just want to reiterate the fact that we are we actually are very pleased with our progress since we implemented our new strategic vision for the company a little over a year ago, and acting on the information that we have learned, accelerating our traction in the marketplace with many of the companies that I mentioned in my remarks. So if there are no other questions, I want to thank you all for participating. I thank you for your continued support. And I thank you for remaining involved in the company and we look forward to reporting again soon. Thank you.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.

Follow Predictive Oncology Inc. (NASDAQ:POAI)

Page 3 of 3